{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:28:55Z","timestamp":1769012935411,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12889-017-4076-3","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T11:33:33Z","timestamp":1490700813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend"],"prefix":"10.1186","volume":"17","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Gervais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1200-6755","authenticated-orcid":false,"given":"Kyle","family":"Dunton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Largeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,28]]},"reference":[{"key":"4076_CR1","unstructured":"Centers for Disease Control and Prevention. Genital HPV infection \u2013 CDC fact sheet. Available at, http:\/\/www.cdc.gov\/std\/hpv\/stdfact-hpv.htm , Accessed 6 Jan 2014."},{"key":"4076_CR2","unstructured":"World health organization. Comprehensive cervical cancer control. A guide to essential practice. 2nd ed. 2014."},{"key":"4076_CR3","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S Sanjose","year":"2010","unstructured":"Sanjose S, Quint WGV, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048\u201356.","journal-title":"Lancet Oncol"},{"issue":"1 Suppl","key":"4076_CR4","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.ygyno.2010.04.004","volume":"118","author":"J Schiller JT","year":"2010","unstructured":"Schiller JT J, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol. 2010;118(1 Suppl):S12\u20137. doi: 10.1016\/j.ygyno.2010.04.004 .","journal-title":"Gynecol Oncol"},{"issue":"2","key":"4076_CR5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/MMBR.68.2.362-372.2004","volume":"68","author":"MS Longworth","year":"2004","unstructured":"Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev. 2004;68(2):362\u201372.","journal-title":"Microbiol Mol Biol Rev"},{"key":"4076_CR6","unstructured":"National Health Services. Genital warts. Available at http:\/\/www.nhs.uk\/conditions\/genital_warts\/pages\/introduction.aspx , Accessed 6 Jan 2014."},{"key":"4076_CR7","unstructured":"European Centre for Disease Prevention and Control. Introduction of HPV vaccines in European Union countries \u2013 an update. Available at http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/20120905_GUI_HPV_vaccine_update.pdf. Accessed 6 Jan 2014."},{"key":"4076_CR8","unstructured":"Centres for disease control and prevention. Human papillomavirus (HPV) \u2013 associated cancers. Available at: http:\/\/www.cdc.gov\/cancer\/hpv\/statistics\/ . Accessed 16 Dec 2014."},{"key":"4076_CR9","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1136\/bmj.e670","volume":"344","author":"IM Kok de","year":"2012","unstructured":"de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ. 2012;344:e670. doi: 10.1136\/bmj.e670 .","journal-title":"BMJ"},{"issue":"5","key":"4076_CR10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.21955","volume":"119","author":"J Cuzick","year":"2006","unstructured":"Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095\u2013101.","journal-title":"Int J Cancer"},{"key":"4076_CR11","unstructured":"Canadian Cancer Society. Cervical cancer statistics. Available at http:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/cervical\/statistics\/?region\u2009=\u2009on , Accessed 27 July 2016."},{"key":"4076_CR12","unstructured":"Australian Government. Cervical cancer in Australia. Accessed 27th, July 2016 http:\/\/www.cervix.cz\/index-en.php?pg=professionals--cervical-cancer-epidemiology"},{"key":"4076_CR13","unstructured":"American Cancer Society. Cervical Cancer. http:\/\/www.cancer.org\/cancer\/cervicalcancer\/detailedguide\/cervical-cancer-key-statistics . Accessed 27 July 2016."},{"key":"4076_CR14","first-page":"2035","volume-title":"Principles and practice of infectious diseases","author":"W Bonnez","year":"2010","unstructured":"Bonnez W, Reichman RC. Papillomaviruses. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone Elsevier; 2010. p. 2035\u201349.","edition":"7"},{"issue":"8","key":"4076_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/apm.12279","volume":"122","author":"E Lynge","year":"2014","unstructured":"Lynge E, Rygaard C, Baillet M, Dug\u00fae A, Sander B, Bonde J, Rebolj M. Cervical cancer screening at crossroads. Apmis. 2014;122(8):667\u201373. doi: 10.1111\/apm.12279 .","journal-title":"Apmis"},{"issue":"Suppl 1","key":"4076_CR16","first-page":"S2","volume":"4","author":"RK Gibb","year":"2011","unstructured":"Gibb RK, Martens MG. The impact of liquid-based cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol. 2011;4 Suppl 1:S2\u2013S11.","journal-title":"Rev Obstet Gynecol"},{"key":"4076_CR17","doi-asserted-by":"crossref","unstructured":"Tota J, Ramana-Kumar A, El-Khatib Z, Franco E. The road ahead for cervical cancer prevention and control. Current Oncology. 2014;21(2). http:\/\/dx.doi.org\/10.3747\/co.21.1720 .","DOI":"10.3747\/co.21.1720"},{"key":"4076_CR18","doi-asserted-by":"crossref","unstructured":"Powell N, Cuschieri K, Cubie H, Hibbitts S, et al. Cervical cancers associated with human papillomavirus types 16, 18 and 45 are diagnosed in younger women than cancers associated with other types: A cross-sectional observational study in Wales and Scotland (UK). J Clin Virol. 2013:1\u20134. http:\/\/dx.doi.org\/10.1016\/j.jcv.2013.08.020 .","DOI":"10.1016\/j.jcv.2013.08.020"},{"key":"4076_CR19","doi-asserted-by":"crossref","first-page":"b2968","DOI":"10.1136\/bmj.b2968","volume":"339","author":"P Sasieni","year":"2009","unstructured":"Sasieni P. Research Effectiveness of cervical screening with age: population based case\u2013control study of prospectively recorded data. BMJ. 2009;339:b2968. doi: http:\/\/dx.doi.org\/10.1136\/bmj.b2968 .","journal-title":"BMJ"},{"issue":"9916","key":"4076_CR20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","volume":"383","author":"G Ronco","year":"2014","unstructured":"Ronco G, Dillner J, Elfstr\u00f6m K, Tunesi S, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524\u201332. doi: http:\/\/dx.doi.org\/10.1016\/S0140-6736(13)62218-7 .","journal-title":"Lancet"},{"key":"4076_CR21","unstructured":"Gardasil. Electronic Medicines Compendium. From: http:\/\/www.medicines.org.uk\/emc\/medicine\/19016\/SPC\/gardasil\/ Accessed: 6 Oct 2014."},{"key":"4076_CR22","unstructured":"Cervarix. Electronic Medicines Compendium. From: http:\/\/www.medicines.org.uk\/emc\/medicine\/20204\/SPC\/Cervarix\/ Accessed: 6 Oct 2014."},{"key":"4076_CR23","doi-asserted-by":"crossref","unstructured":"Hartwig S, Baldauf J, Dominiak-Felden G, et al. Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation. Papillomavirus Res. 2015. (in press) HPV vaccine compared to first generation HPV vaccines.","DOI":"10.1016\/j.pvr.2015.06.003"},{"key":"4076_CR24","unstructured":"Brisson M. Incremental Cost-Effectiveness of the 9-valent vs. the 4-valent HPV vaccine in the U.S. Universit\u00e9 Laval.\u00a0In: Advisory Committee on Immunization Practices (ACIP) meeting. Atlanta; 2014."},{"key":"4076_CR25","doi-asserted-by":"crossref","unstructured":"Mendes D, Bains T, Vanni T, et al. Systematic review of model-based cervical screening evaluations. BMC Cancer. 2015;15:334.","DOI":"10.1186\/s12885-015-1332-8"},{"issue":"S5","key":"4076_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.vaccine.2012.06.091","volume":"30","author":"K Canfell","year":"2012","unstructured":"Canfell K, Chesson H, Kulasingham SL, Berkhof J, Diaz M, Kim JJ. Modelling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30(S5):167. doi: 10.1016\/j.vaccine.2012.06.091 .","journal-title":"Vaccine"},{"issue":"6","key":"4076_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.290.6.781","volume":"290","author":"SI Kulasingam","year":"2003","unstructured":"Kulasingam SI, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290(6):781\u201390. doi: 10.1001\/jama.290.6.781 .","journal-title":"JAMA"},{"issue":"1","key":"4076_CR28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0901.020168","volume":"6","author":"GD Sanders","year":"2003","unstructured":"Sanders GD, Taira AV. Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;6(1):37\u201345.","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"4076_CR29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/jnci\/djh104","volume":"96","author":"SJ Goldie","year":"2004","unstructured":"Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch X, Franco E. Projected clinical benefits and cost\u2013effectiveness of a human papillomavirus 16\/18 vaccine. J Natl Cancer Inst. 2004;96(8):604\u201316. doi: 10.1093\/jnci\/djh104 .","journal-title":"J Natl Cancer Inst"},{"key":"4076_CR30","doi-asserted-by":"publisher","first-page":"b3884","DOI":"10.1136\/bmj.b3884","volume":"339","author":"JJ Kim","year":"2009","unstructured":"Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884. doi: 10.1136\/bmj.b3884 .","journal-title":"BMJ"},{"issue":"8","key":"4076_CR31","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMsa0707052","volume":"359","author":"JJ Kim","year":"2008","unstructured":"Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Eng J. 2008;359(8):821\u201332. doi: 10.1056\/NEJMsa0707052 .","journal-title":"N Eng J"},{"issue":"11","key":"4076_CR32","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","volume":"10","author":"AV Taira","year":"2004","unstructured":"Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10(11):1915\u201324.","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"4076_CR33","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/jnci\/djn019","volume":"100","author":"JD Goldhaber-Fiebert","year":"2008","unstructured":"Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. J Natl Cancer Inst. 2008;100(5):308\u201320. doi: 10.1093\/jnci\/djn019 .","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"4076_CR34","doi-asserted-by":"crossref","first-page":"538","DOI":"10.7326\/0003-4819-151-8-200910200-00007","volume":"151","author":"JJ Kim","year":"2009","unstructured":"Kim JJ, Orthendahl BS, Goldie SJ. Cost-effectiveness of HPV vaccination and cervical cancer screening I women over age 30 in the United States. Ann Intern Med. 2009;151(8):538\u201345.","journal-title":"Ann Intern Med"},{"key":"4076_CR35","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1016\/j.vaccine.2009.06.043","volume":"27","author":"VMH Coupe","year":"2009","unstructured":"Coupe VMH, de Melker HE, Snijders PJF, Meijer CJLM, Berkhof J. How to screen for cervical cancer after HPV16\/18 vaccination in the Netherlands. Vaccine. 2009;27:5111\u20139. doi: 10.1016\/j.vaccine.2009.06.043 .","journal-title":"Vaccine"},{"key":"4076_CR36","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/ijc.24000","volume":"124","author":"VMH Coupe","year":"2008","unstructured":"Coupe VMH, van Ginkel J, de Melker HE, Snijders PJF, Meijer CJLM, Berkhof J. HPV16\/18 vaccination to prevent cervical cancer in the Netherlands: model-based cost-effectiveness. Int J Cancer. 2008;124:970\u20138. doi: 10.1002\/ijc.24000 .","journal-title":"Int J Cancer"},{"issue":"10","key":"4076_CR37","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.vaccine.2012.01.001","volume":"30","author":"VMH Coupe","year":"2012","unstructured":"Coupe VMH, Bogaards JA, Meijer CJLM, Berkhof J. Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening. Vaccine. 2012;30(10):1913\u2013822. doi: 10.1016\/j.vaccine.2012.01.001 .","journal-title":"Vaccine"},{"key":"4076_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1258\/jms.2010.010019","volume":"17","author":"G Accetta","year":"2010","unstructured":"Accetta G, Biggeri A, Carreras G, Lippi G, Carozzi FM, Confortini M, Zappa M, Paci E. Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis. J Med Screen. 2010;17:181\u20139. doi: 10.1258\/jms.2010.010019 .","journal-title":"J Med Screen"},{"key":"4076_CR39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1071\/SH07043","volume":"4","author":"S Kulasingham","year":"2007","unstructured":"Kulasingham S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G. A cost-effectiveness analysis of adding a human papillomavirus to the Australian national screening program. Sex Health. 2007;4:165\u201375. http:\/\/dx.doi.org\/10.1071\/SH07043 .","journal-title":"Sex Health"},{"key":"4076_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.vaccine.2011.10.067","volume":"30","author":"SP Tully","year":"2011","unstructured":"Tully SP, Anonychuk AM, Sanchez DM, Galvani AP, Bauch CT. Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. Vaccine. 2011;30:425\u201335. doi: 10.1016\/j.vaccine.2011.10.067 .","journal-title":"Vaccine"},{"key":"4076_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00038-010-0216-6","volume":"56","author":"N Demarteau","year":"2009","unstructured":"Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health. 2009;56:153\u201362. doi: 10.1007\/s00038-010-0216-6 .","journal-title":"Int J Public Health"},{"key":"4076_CR42","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/bjc.2012.94","volume":"106","author":"EA Burger","year":"2012","unstructured":"Burger EA, Ortendahl JD, Sy S, Kritiansen IS, Kim JJ. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer. 2012;106:1571\u20138. doi: 10.1038\/bjc.2012.94 .","journal-title":"Br J Cancer"},{"key":"4076_CR43","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1016\/j.ejca.2010.06.016","volume":"46","author":"M Diaz","year":"2010","unstructured":"Diaz M, de Sanjose S, Orthendahl J, O\u2019Shea M, Goldie SJ, Bosch FX, Kim JJ. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer. 2010;46:2973\u201385. doi: 10.1016\/j.ejca.2010.06.016 .","journal-title":"Eur J Cancer"},{"key":"4076_CR44","doi-asserted-by":"crossref","first-page":"H71","DOI":"10.1016\/j.vaccine.2013.04.086","volume":"31S","author":"J Berkhof","year":"2013","unstructured":"Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine. 2013;31S:H71\u20139. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2013.04.086 .","journal-title":"Vaccine"},{"key":"4076_CR45","doi-asserted-by":"publisher","unstructured":"Simms K, Smith M, Lew JB, et al. How often will cervical screening be required in women offered next generation nonavalent HPV vaccine? Int J Cancer.\u00a02016 Dec 15;139(12):2771-80. doi: 10.1002\/ijc.30392 .","DOI":"10.1002\/ijc.30392"},{"key":"4076_CR46","doi-asserted-by":"publisher","unstructured":"Cuzick J. Gardasil 9 joins the fight against cervix cancer. Expert Rev Vaccines. 2015;14(8):1047\u20139. doi: 10.1586\/14760584.2015.1051470 .","DOI":"10.1586\/14760584.2015.1051470"},{"key":"4076_CR47","unstructured":"Canfell K, Lew J, Simms K, Kang Y, Xu X, Caruana M, Walker R, Smith M. Optimal screening strategies in the era of vaccination in terms of cost-effectiveness \u2013 Australia. Eurogin; 2015. Abstract SS 6\u20131.\u00a0Lowy Cancer Research Centre, Prince of Wales Clinical School, UNSW Australia, Sydney, Australia."},{"issue":"1","key":"4076_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0145548","volume":"11","author":"K Naber","year":"2016","unstructured":"Naber K, Matthijsse S, Rozemeijer K, et al. Cervical cancer screening in partly HPV vaccinated cohorts \u2013 a cost effectiveness analysis. PLoS One. 2016;11(1):1\u201315. doi: 10.1371\/journal.pone.0145548 .","journal-title":"PLoS One"},{"issue":"1","key":"4076_CR49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.vaccine.2014.08.048","volume":"33","author":"L Simonella","year":"2015","unstructured":"Simonella L, Canfell K. Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries. Vaccine. 2015;33(1):34\u201351. doi: 10.1016\/j.vaccine.2014.08.048 . Epub 2014 Aug 27. Review.","journal-title":"Vaccine"},{"key":"4076_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.02.016","author":"B Sander","year":"2016","unstructured":"Sander B, Wong WW, Yeung MW, Ormanidhi O, Atkin K, Murphy J, Krahn M, Deeks SL. The cost-utility of integrated cervical cancer prevention strategies in the Ontario setting - Can we do better? Vaccine. 2016. doi: 10.1016\/j.vaccine.2016.02.016 . [Epub ahead of print] PubMed PMID: 26892739.","journal-title":"Vaccine"},{"key":"4076_CR51","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2147\/IJWH.S50365","volume":"6","author":"R Vincenzo De","year":"2014","unstructured":"De Vincenzo R, Conte C, Ricci C, Scambia G. Giovanni Capelli Long-term efficacy and safety of human papillomavirus vaccination. Int J Women\u2019s Health. 2014;6:999\u20131010.","journal-title":"Int J Women\u2019s Health"},{"key":"4076_CR52","volume-title":"Comprehensive Cerival Cancer Control \u2013 A guide to essential practice \u2013 2nd edition","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Comprehensive Cerival Cancer Control \u2013 A guide to essential practice \u2013 2nd edition. 2014."},{"issue":"1","key":"4076_CR53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1586\/14760584.2015.964213","volume":"14","author":"S Isidean","year":"2015","unstructured":"Isidean S, Tota J, Gagnon J, Franco E. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. Expert Rev Vaccines. 2015;14(1):119\u201333. doi: 10.1586\/14760584.2015.964213 .","journal-title":"Expert Rev Vaccines"},{"key":"4076_CR54","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12885-015-1332-8","volume":"15","author":"D Mendes","year":"2015","unstructured":"Mendes D, Bains I, Vanni T, et al. Systematic review of model-based cervical screening evaluations. BMC Cancer. 2015;15:334. doi: 10.1186\/s12885-015-1332-8 .","journal-title":"BMC Cancer"},{"key":"4076_CR55","unstructured":"Baussano I. Effectiveness and impact of different HPV vaccination and screening strategies. HPV Today; 2014. Number 32\u201333: pp 14.\u00a0Imperial College London."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-017-4076-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T09:40:31Z","timestamp":1498383631000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-017-4076-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,28]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["4076"],"URL":"https:\/\/doi.org\/10.1186\/s12889-017-4076-3","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,28]]},"article-number":"283"}}